1-(2'-Bromobenzyl)-6,7-dihydroxy-N-methyl-tetrahydroisoquinoline and 1,2- Demethyl-nuciferine as Agonists in Human D2 Dopamine Receptors
Certain D2-like dopamine receptor (DR) agonists are useful therapeutically as antiparkinsonian drugs, whereas D2-like DR antagonists or partial agonists are proven effective as antipsychotics. Two isoquinoline derivatives, 1-(2'-bromobenzyl)-6,7- dihydroxy-N-methyl-tetrahydroisoquinoline (Br-BT...
| Autores: | , , , , , , , , |
|---|---|
| Formato: | artículo |
| Fecha de publicación: | 2020 |
| País: | España |
| Recursos: | Universidad de Santiago de Compostela (USC) |
| Repositorio: | Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela |
| Idioma: | inglés |
| OAI Identifier: | oai:minerva.usc.gal:10347/39403 |
| Acesso em linha: | https://hdl.handle.net/10347/39403 |
| Access Level: | acceso abierto |
| Palavra-chave: | Agonists Assays Mixtures Receptors Silica 3209 Farmacología |
| Resumo: | Certain D2-like dopamine receptor (DR) agonists are useful therapeutically as antiparkinsonian drugs, whereas D2-like DR antagonists or partial agonists are proven effective as antipsychotics. Two isoquinoline derivatives, 1-(2'-bromobenzyl)-6,7- dihydroxy-N-methyl-tetrahydroisoquinoline (Br-BTHIQ, 1) and 1,2-demethyl-nuciferine (aporphine 2) were herein synthesized, and their dopaminergic affinity in cloned human D2R, D3R and D4R subtypes and their behavior as agonists/ antagonists was evaluated. They showed affinity values (Ki) for hD2, hD3 and hD4 DR within the nanomolar range. The trends in affinity were hD4R >> hD3R > hD2R for Br-BTHIQ 1, and hD2R > hD4R > hD3R for 1,2-demethyl-nuciferine (2). The functional assays of cAMP signaling at human D2R showed a partial agonist effect for Br-BTHIQ 1 and full agonist behavior for aporphine 2 with EC50 values of 2.95 μM and 10.2 μM, respectively. Therefore, both isoquinolines 1 and 2 have emerged as lead molecules for the synthesis of new therapeutic drugs that ultimately may be useful to prevent schizophrenia and Parkinson’s disease, respectively. |
|---|